Tadalafil is a PDE-5 inhibitor with a long half-life17 and we hypothesise that an improved endothelial dysfunction and microcirculation induced by high-dose tadalafil once daily would reduce whole-body insulin resistance. Here, PDE5A is linked to endothelial dysfunction.